Fig. 2: TTK inhibitors enhance the effect of olaparib in OC cells.
From: TTK activates ATR through RPA2 phosphorylation to promote olaparib resistance in ovarian cancer
A The IC50 of CFI402257 (CFI) in OVCAR8 cells (IC50 = 528.84 nM, 96 h). Data are mean ± SD, n = 3. B The IC50 of BAY1161909 (B909) in OVCAR8 cells (IC50 = 217.31 nM, 96 h) and OV90 cells (IC50 = 358.34 nM, 96 h). Data are mean ± SD, n = 3. C, D MTT, and colony survival assays were performed to assess the efficacy of the combined treatment of CFI and olaparib (OLA) in OVCAR8 and OV90 cells. Data are mean ± SD, n = 3, one-way ANOVA. a: p relative to CFI treatment alone; b: p relative to olaparib treatment alone. The effect of B909 on olaparib sensitivity was evaluated using the MTT assay (E) and colony survival assay (F). Data are mean ± SD, n = 3, one-way ANOVA. a: p relative to B909 treatment alone; b: p relative to olaparib treatment alone. (Data are mean ± SD, *P < 0.05, **P < 0.01, ***P < 0.001, n = 3).
